Friday, November 13, 2020

Cardiomyopathy as the first manifestation of Friedreich's ataxia

›
Rafael Tuzino Leite Neves Maffei; Giulio de los Santos Fortuna; Luca Campolino Rosso; Pedro Dragone Pires; Ivan Rondelli Autops Case Rep, vo...

Epigenetic Regulation of the Clinical Signs of Friedreich’s Disease

›
E. P. Nuzhny, N. Yu. Abramycheva, N. S. Nikolaeva, M. V. Ershova, S. A. Klyushnikov, S. N. Illarioshkin & E. Yu. Fedotova; Neurosci Beha...
Tuesday, November 10, 2020

The Nrf2 induction prevents ferroptosis in Friedreich’s Ataxia

›
Piergiorgio La Rosa, Sara Petrillo, Riccardo Turchi, Francesco Berardinelli, Tommaso Schirinzi, Gessica Vasco, Daniele Lettieri-Barbato, Mar...
Sunday, November 8, 2020

PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia

›
Laura Rodríguez-Pascau, Elena Britti, Pablo Calap-Quintana, Yi Na Dong, Cristina Vergara, Fabien Delaspre, Marta Medina, Jordi Tamarit, Fede...
Friday, November 6, 2020

Electrocardiogram in Friedreich's ataxia: A short‐term surrogate endpoint for treatment efficacy

›
Sandra Mastroianno MD Michele Germano MD Angela Maggio MD Raimondo Massaro MD Domenico Rosario Potenza MD Aldo Russo MD Massimo Carell...
Thursday, November 5, 2020

Effect of Mitochondrial and Cytosolic FXN Isoform Expression on Mitochondrial Dynamics and Metabolism

›
Agrò, M.; Díaz-Nido, J. , Int. J. Mol. Sci. 2020, 21, 8251. doi:10.3390/ijms21218251 (registering DOI) Alternative forms of frataxin have be...
Saturday, October 31, 2020

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

›
Press release, 30 October 2020, Barcelona.  The European Investment Bank (EIB) today announced that it has approved €25 million financing fo...

EL BANCO EUROPEO DE INVERSIONES PROPORCIONA €25M A MINORYX PARA APOYAR EL DESARROLLO DE TERAPIAS INNOVADORAS EN ENFERMEDADES RARAS NEURODEGENERATIVAS.

›
Mataró (Barcelona, España) y Charleroi (Bélgica), 30 de octubre de 2020. Minoryx Therapeutics, una empresa biotecnológica en fase clínica II...
Friday, October 30, 2020

[4Fe-4S] cluster trafficking mediated by Arabidopsis mitochondrial ISCA and NFU proteins

›
Tamanna Azam, Jonathan Przybyla-Toscano, Florence Vignols, Jérémy Couturier, Nicolas Rouhier, and Michael K. Johnson, J. Biol. Chem. jbc.RA1...
Thursday, October 29, 2020

An Overview of the Ferroptosis Hallmarks in Friedreich’s Ataxia

›
Turchi, R.; Faraonio, R.; Lettieri-Barbato, D.; Aquilano, K. Biomolecules 2020, 10, 1489. doi:10.3390/biom10111489   Even though ferroptosis...